Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715715 | 0.95 | GPR119 (0.55) | GPR119HPGDKDM4ERECQLEPHX1 | |
| SCHEMBL470837 | 0.90 | GPR119 (0.67) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL31540008 | 0.88 | GPR119 (0.47) | GPR119NR1H2 | |
| SCHEMBL31540076 | 0.88 | GPR119 (0.47) | GPR119NR1H2 | |
| SCHEMBL23693082 | 0.88 | NR1H2 (0.50) | GPR119HPGDNR1H2 | |
| SCHEMBL26635067 | 0.88 | GPR119 (0.56) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL4097772 | 0.87 | GPR119 (0.60) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL14497234 | 0.87 | GPR119 (0.50) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL17656738 | 0.87 | GPR119 (0.47) | GPR119HPGDNR1H2 | |
| SCHEMBL15000982 | 0.87 | GPR119 (0.47) | GPR119HPGDNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-5994356-A | ANTICOAGULANT | KARL THOMAE (DE) | 1999-11-30 | — | — | US | disclosed |
| EP-0892783-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | Dr. Karl Thomae GmbH (DE) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997037975-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | DR. KARL THOMAE GMBH (DE) | 1997-10-16 | — | — | WO | disclosed |
| EP-0638553-A1 | Carboxylic acid amides having a terminal carboxylic acid group as aggregation inhibiting drugs | Dr. Karl Thomae GmbH (DE) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885HPGD 3843/4885KDM4E 190/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885HPGD 3843/4885KDM4E 190/4885 |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | GPR119 2659/4885HPGD 3048/4885KDM4E 2379/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | GPR119 2190/4885HPGD 4572/4885KDM4E 988/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885HPGD 3843/4885KDM4E 190/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885HPGD 3843/4885KDM4E 190/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | GPR119 4342/4885HPGD 1488/4885KDM4E 1060/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | GPR119 2528/4885HPGD 3940/4885KDM4E 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.